GLP-1 Receptor Agonists and Kidney Outcomes: Meta-analysis of Cardiovascular Outcome Trials

glp1 · Lancet Diabetes & Endocrinology · 2021

Across 8 trials and 60,080 participants, GLP-1 agonists reduced kidney composite outcomes by 21% and slowed eGFR decline.

Authors

Sattar N, Lee MMY, Kristensen SL, et al.

Across 8 trials and 60,080 participants, GLP-1 agonists reduced kidney composite outcomes by 21% and slowed eGFR decline.